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ABSTRACT 
The serodiagnosis of Rift Valley fever (RVF) relies on the use of inactivated whole virus based reagents 
which present biosafety, financial and operational constraints. There are no vaccines for humans, the 
availability of animal vaccines is limited and they have several drawbacks. The aim of this study was to 
evaluate a bacterially expressed recombinant RVF virus (RVFV) nucleocapsid protein (recNP) as a safe 
immunodiagnostic reagent, and an immunogen in a mouse and host animal model. Several enzyme-linked 
immunosorbent assays (ELISAs) were developed in this study, enabling sensitive and specific detection 
of antibodies and RVFV antigen in human and animal specimens. The recNP was combined with 
different adjuvants and used to immunize mice and sheep subsequently challenged with a virulent wild 
type RVFV strain. Depending on the recNP/adjuvant combination, protection against disease in mice 
ranged between 17 and 100%, with sterilizing immunity elicited in some experimental groups, compared 
to 100% morbidity/mortality and excessive viral replication in adjuvant and PBS control mice. 
Immunization with recNP combined with Alhydrogel, an adjuvant that biases immunity towards Th2 
humoral immunity, that yielded 100% protection, induced an earlier and stronger type I interferon 
response in mice after challenge, compared to repression of the same gene in adjuvant and PBS control 
mice. There was massive activation of pro-inflammatory responses and genes with pro-apoptotic effects 
in the livers of control mice at the acute phase of infection, accompanied by high viral replication, 
possibly contributing to the pathology of the liver. There was also evidence of activation and repression 
of several genes involved in activation of B- and T-cell immunity in control mice, some indicating 
possible immune evasion by the challenge virus. Immunization of sheep with the same recNP/adjuvant 
combinations were, however, not able to decrease replication of challenge virus. The recNP based 
ELISAs are an important addition to and improvement of the currently available serodiagnostic tests for 
RVF. The mechanism by which recNP immunization protects mice from developing severe disease 
during the acute phase of infection is now better understood, but the mechanism for earlier clearance of 
the virus needs further investigation. 
